Tissue Regenix Group (TRX)

Sector:

Financials

Index:

FTSE AIM All-Share

40.50p
   
  • Change Today:
    -2.00p
  • 52 Week High: 74.00p
  • 52 Week Low: 39.00p
  • Currency: UK Pounds
  • Shares Issued: 71.40m
  • Volume: 46,834
  • Market Cap: £28.92m
  • RiskGrade: 22
  • Beta: 0.00

Mike Barker installed as finance chief at Tissue Regenix

By Josh White

Date: Wednesday 28 Aug 2019

LONDON (ShareCast) - (Sharecast News) - Regenerative medical devices company Tissue Regenix Group announced the appointment of Mike Barker as its chief financial officer on Wednesday.
The AIM-traded firm said Barker would join the group as CFO and as an executive director on the board with immediate effect, having supported the company since the beginning of the year as interim finance director.

It said Barker, a Chartered Accountant for more than 20 years, was bringing experience of both AIM-listed and private businesses with him.

After training with Deloitte, he reportedly spent 10 years in its corporate finance advisory business working on private equity transactions, before setting up his own consultancy business to assist small to medium enterprises in the delivery of strategic plans.

During that time, Tissue Regenix said he worked "closely" with the management team of Quantum Pharma - a UK manufacturer and supplier of unlicensed medicines and hard-to-source products, acquired by Clinigen Group in 2017, to deliver strategic projects before holding the position of group corporate development director.

"It's a pleasure to welcome Mike to the executive team," said executive director John Samuel.

"He is well acquainted with the business, having supported the group since the beginning of the year.

"His experience in AIM listed businesses and contribution to strategic planning will augment and strengthen our management and executive teams as we continue to improve the efficiency of our operations across the business to meet the increasing demand for our products."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

TRX Market Data

Currency UK Pounds
Share Price 40.50p
Change Today -2.00p
% Change -4.71 %
52 Week High 74.00p
52 Week Low 39.00p
Volume 46,834
Shares Issued 71.40m
Market Cap £28.92m
Beta 0.00
RiskGrade 22

TRX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
29.7% below the market average29.7% below the market average29.7% below the market average29.7% below the market average29.7% below the market average
35.24% below the sector average35.24% below the sector average35.24% below the sector average35.24% below the sector average35.24% below the sector average
Price Trend
68.78% below the market average68.78% below the market average68.78% below the market average68.78% below the market average68.78% below the market average
78.38% below the sector average78.38% below the sector average78.38% below the sector average78.38% below the sector average78.38% below the sector average
Income Not Available
Growth
31.94% above the market average31.94% above the market average31.94% above the market average31.94% above the market average31.94% above the market average
36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average

TRX Dividends

No dividends found

Trades for 12-Mar-2025

Time Volume / Share Price
15:02 6,000 @ 40.90p
14:01 2,829 @ 39.00p
14:00 2,829 @ 39.20p
14:00 1,422 @ 39.20p
14:00 1,407 @ 39.20p

TRX Key Personnel

CEO Daniel Lee
CFO David Cocke

Top of Page